See more : BCE Inc. (BCEFF) Income Statement Analysis – Financial Results
Complete financial analysis of DURECT Corporation (DRRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DURECT Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Takeda Pharmaceutical Company Limited (TAK) Income Statement Analysis – Financial Results
- Ashoka Buildcon Limited (ASHOKA.NS) Income Statement Analysis – Financial Results
- Seiko Electric Co., Ltd. (6653.T) Income Statement Analysis – Financial Results
- Kiplin Metals Inc. (KIP.V) Income Statement Analysis – Financial Results
- Harmonic Drive Systems Inc. (HSYDF) Income Statement Analysis – Financial Results
DURECT Corporation (DRRX)
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.55M | 19.28M | 13.98M | 30.11M | 29.56M | 18.56M | 49.17M | 14.03M | 19.12M | 19.40M | 15.33M | 53.07M | 33.49M | 31.59M | 24.29M | 25.96M | 30.68M | 21.89M | 28.57M | 13.85M | 11.84M | 7.19M | 6.52M | 3.16M | 86.00K |
| Cost of Revenue | 1.72M | 1.59M | 1.96M | 1.41M | 4.14M | 4.26M | 6.63M | 5.29M | 3.91M | 5.69M | 4.84M | 4.65M | 4.71M | 4.28M | 5.34M | 3.37M | 3.23M | 3.25M | 2.82M | 2.73M | 2.43M | 3.09M | 3.40M | 1.29M | -272.00K |
| Gross Profit | 6.83M | 17.70M | 12.02M | 28.71M | 25.42M | 14.30M | 42.54M | 8.74M | 15.22M | 13.72M | 10.49M | 48.42M | 28.77M | 27.32M | 18.95M | 22.59M | 27.45M | 18.65M | 25.76M | 11.12M | 9.41M | 4.10M | 3.13M | 1.86M | 358.00K |
| Gross Profit Ratio | 79.91% | 91.76% | 86.01% | 95.33% | 85.99% | 77.04% | 86.51% | 62.28% | 79.58% | 70.69% | 68.44% | 91.23% | 85.93% | 86.47% | 78.01% | 87.04% | 89.49% | 85.16% | 90.15% | 80.30% | 79.49% | 57.05% | 47.92% | 59.08% | 416.28% |
| Research & Development | 29.35M | 36.86M | 31.85M | 27.71M | 30.21M | 25.50M | 31.61M | 29.27M | 24.32M | 22.43M | 18.95M | 20.27M | 34.05M | 36.21M | 34.91M | 39.41M | 38.34M | 37.24M | 28.90M | 24.23M | 20.95M | 29.55M | 24.57M | 13.34M | 6.36M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.02M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.36M | 15.92M | 14.45M | 13.61M | 14.36M | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.14M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 12.08M | 9.85M | 3.04M |
| Other Expenses | 0.00 | 23.66M | 25.52M | 3.77M | 12.08M | 17.29M | 8.03M | 27.39M | 16.49M | 14.17M | 15.36M | 0.00 | 11.69M | 16.12M | 22.45M | 48.00K | 31.00K | 424.00K | 1.21M | 1.25M | 1.34M | 1.34M | 1.84M | 1.50M | 311.00K |
| Operating Expenses | 43.72M | 52.78M | 46.30M | 41.32M | 44.57M | 37.92M | 44.77M | 41.10M | 35.88M | 34.71M | 31.65M | 32.36M | 47.63M | 51.15M | 50.05M | 68.40M | 51.99M | 50.08M | 41.38M | 35.43M | 30.69M | 43.07M | 38.50M | 24.69M | 9.72M |
| Cost & Expenses | 45.43M | 54.37M | 48.25M | 42.73M | 48.72M | 42.18M | 51.41M | 46.39M | 39.79M | 40.40M | 36.49M | 37.01M | 52.34M | 55.43M | 55.39M | 71.77M | 55.22M | 53.33M | 44.20M | 38.16M | 33.11M | 46.15M | 41.90M | 25.98M | 9.45M |
| Interest Income | 2.13M | 2.15M | 156.00K | 517.00K | 1.07M | 870.00K | 967.00K | 143.00K | 237.00K | 39.00K | 0.00 | 151.00K | 134.00K | 943.00K | 420.00K | 1.55M | 0.00 | 3.83M | 2.27M | 0.00 | 1.04M | 0.00 | 0.00 | 3.10M | 0.00 |
| Interest Expense | 2.79M | 2.40M | 2.15M | 2.24M | 2.50M | 2.57M | 2.43M | 2.29M | 2.24M | 1.15M | 290.00K | 7.00K | 46.00K | 6.00K | 36.00K | 789.00K | 2.63M | 3.44M | 4.36M | 0.00 | 2.46M | 0.00 | 0.00 | 131.00K | 0.00 |
| Depreciation & Amortization | 148.00K | 150.00K | 132.00K | 297.00K | 291.00K | 254.00K | 437.00K | 416.00K | 425.00K | 601.00K | 558.00K | 964.00K | 1.18M | 2.25M | 2.51M | 48.00K | 2.32M | 2.46M | 3.17M | 4.64M | 4.75M | 4.32M | 3.30M | 1.50M | 311.00K |
| EBITDA | -24.68M | -32.78M | -33.99M | -11.80M | -18.58M | -22.50M | -833.00K | -31.81M | -20.00M | -20.36M | -20.60M | 17.16M | -17.59M | -20.64M | -27.75M | -45.76M | -22.22M | -28.97M | -12.46M | -18.43M | -16.53M | -34.65M | -32.07M | -21.32M | -9.05M |
| EBITDA Ratio | -288.77% | -170.79% | -244.09% | -40.18% | -61.15% | -122.54% | -2.58% | -229.74% | -106.81% | -108.03% | -138.08% | 32.36% | -56.30% | -75.45% | -129.75% | -176.30% | -70.11% | -121.89% | -42.20% | -141.98% | -139.70% | -482.25% | -276.58% | -675.85% | -10,520.93% |
| Operating Income | -36.88M | -35.08M | -34.27M | -12.62M | -19.15M | -23.62M | -2.24M | -32.36M | -20.66M | -21.00M | -21.16M | 16.06M | -18.85M | -23.84M | -31.10M | -45.81M | -24.54M | -31.44M | -15.63M | -24.31M | -21.28M | -38.97M | -49.40M | -22.82M | -9.36M |
| Operating Income Ratio | -431.49% | -181.93% | -245.21% | -41.89% | -64.78% | -127.23% | -4.55% | -230.76% | -108.05% | -108.23% | -138.08% | 30.25% | -56.30% | -75.45% | -128.02% | -176.48% | -80.00% | -143.58% | -54.70% | -175.48% | -179.80% | -542.37% | -757.23% | -723.39% | -10,882.56% |
| Total Other Income/Expenses | 9.26M | -251.00K | -1.99M | -1.72M | -1.43M | -1.70M | -1.46M | -2.15M | -2.00M | -1.11M | -290.00K | 144.00K | 88.00K | 937.00K | 811.00K | 758.00K | 202.00K | -1.89M | -2.50M | -3.31M | -1.42M | 1.80M | 4.47M | 0.00 | 0.00 |
| Income Before Tax | -27.62M | -35.33M | -36.27M | -14.34M | -20.58M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.29M | -43.91M | -24.34M | -33.33M | -18.12M | -27.62M | -22.70M | -37.17M | -44.93M | 0.00 | 0.00 |
| Income Before Tax Ratio | -323.16% | -183.23% | -259.46% | -47.61% | -69.60% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -124.68% | -169.15% | -79.34% | -152.22% | -63.43% | -199.37% | -191.79% | -517.37% | -688.66% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 251.00K | 1.86M | -11.81M | 2.21M | 870.00K | 530.00K | -273.00K | -188.00K | -562.00K | -558.00K | 151.00K | -1.18M | -2.25M | -2.89M | -12.69M | -202.00K | 1.89M | 4.00K | 18.00K | 0.00 | 0.00 | 9.56M | -2.97M | -651.00K |
| Net Income | -27.62M | -35.58M | -38.13M | -2.52M | -22.79M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.72M | -45.05M | -24.34M | -33.33M | -18.13M | -27.64M | -22.70M | -37.17M | -44.93M | -19.85M | -8.71M |
| Net Income Ratio | -323.16% | -184.54% | -272.77% | -8.38% | -77.08% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -126.44% | -173.56% | -79.34% | -152.22% | -63.45% | -199.50% | -191.79% | -517.37% | -688.66% | -629.19% | -10,125.58% |
| EPS | -1.22 | -1.56 | -1.69 | -0.13 | -1.28 | -1.60 | -0.25 | -2.60 | -1.91 | -2.00 | -2.10 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -11.60 | -3.66 |
| EPS Diluted | -1.20 | -1.56 | -1.69 | -0.13 | -1.28 | -1.58 | -0.25 | -2.59 | -1.91 | -1.98 | -2.08 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -6.01 | -3.66 |
| Weighted Avg Shares Out | 26.26M | 22.78M | 22.50M | 19.95M | 17.80M | 15.84M | 14.53M | 13.27M | 11.85M | 11.06M | 10.22M | 8.84M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 1.71M | 2.38M |
| Weighted Avg Shares Out (Dil) | 26.52M | 22.78M | 22.50M | 19.95M | 17.80M | 15.98M | 14.53M | 13.32M | 11.85M | 11.17M | 10.31M | 8.86M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 3.31M | 2.38M |
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that...
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a...
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer Carl Byrnes - Northland...
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
- Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif.
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that...
Why Is Durect (DRRX) Stock Down 64% Today?
Durect (NASDAQ: DRRX ) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency of larsucosterol in treating patients with severe alcohol-associated hepatitis.
Source: https://incomestatements.info
Category: Stock Reports